TPI Reports Second Quarter Fiscal Year 2014 Financial Results - KPLC 7 News, Lake Charles, Louisiana

TPI Reports Second Quarter Fiscal Year 2014 Financial Results

  • HealthMore>>

  • FDA to propose e-cigarette regulations

    FDA to propose e-cigarette regulations

    © FDA© FDA
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.More >>
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.More >>
  • People seek out health info when famous person dies

    People seek out health info when famous person dies

    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
  • 1 in 13 U.S. schoolkids takes psych meds

    1 in 13 U.S. schoolkids takes psych meds

    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.More >>
    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Tianyin Pharmaceutical Inc.

CHENGDU, China, Feb. 14, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the second quarter fiscal year 2014.

Second Quarter Fiscal 2014 Ended December 31, 2013 Financial Highlights:

  • Revenue was $13.9 million versus $17.6 million in the second quarter FY 2013, a decrease of 21% year over year;
  • Gross profit was $6.2 million with gross margin at 45% versus gross profit of $6.8 million with gross margin at 39% in the second quarter FY 2013;
  • Operating income was $2.5 million, compared with $2.6 million in the second quarter FY 2013;
  • Net Income was $1.7 million compared with $1.8 million in the second quarter FY 2013;
  • Earnings per share of $0.06 per basic and diluted share, compared with $0.06 per basic and diluted share in the second quarter FY 2013; 
  • Cash and cash equivalents totaled $31.3 million on December 31, 2013.

Comparison of results for the three months ended December 31, 2013 and 2012:



Three Months Ended

December 31,



2013



2012



(In millions)

Sales


$

13.9



$

17.6

Cost of sales


$

7.7



$

10.8

Gross profit


$

6.2



$

6.8

Total operating expenses


$

3.8



$

4.2

Provision for income taxes


$

0.7



$

0.7

Net income


$

1.7



$

1.8

Sales for the quarter ended December 31, 2013 was $13.9 million, a decrease of 21% versus $17.6 million for the quarter ended December 31, 2012. The sales decrease reflected the continuous pricing pressure and restrictive sales policies in generic products compared with the same period last year.

In the second quarter FY 2014, our top five core product sales were:

  1. Gingko mihuan oral liquid (GMOL) for stroke and cardiovascular disorders: $6.3 million
  2. Mycophenolate mofetil capsules (MM) for renal transplant: $2.1 million
  3. Azithromycin tablets (AZI) for infection: $0.6 million
  4. Qingre jiedu oral liquid (QR): $0.7 million
  5. Qianlie Shule capsules (QS) for prostate conditions: $0.5 million

These core products totaled $10.1 million in sales, representing 73% of our revenue in the second quarter FY 2014. With the pricing restriction and sales decrease in generic segment, we observed concentration of sales in the core product segment. The inclusion of GMOL in a number of Provincial EDL (PEDL) lists, such as the provinces of Henan, Shandong, Sichuan and Guangdong, and the City of Chongqing, has supported a meaningful sales increase in fiscal year 2013 continuing in fiscal year 2014. Before further provincial EDL penetration by GMOL, we consider that the current level of GMOL sales stabilized. The contribution from our distribution business through TMT for the past six months ended December 31, 2013 amounted to $2.2 million at 12% gross margin.

Cost of Sales for the quarter ended December 31, 2013 was $7.7 million or 55% of sales, versus $10.8 million or 61% of sales for the quarter ended December 31, 2012. The percentage decrease in our cost of sales year over year was mainly attributable to a greater mix of higher margin products augmented by a pricing stabilization of our lower margin generic products. 

Gross Margin for the quarter ended December 31, 2013 was 45% versus 39% for the quarter ended December 31, 2012. The gross margin improvement was predominately the result of a greater mix of higher margin products being sold during the period. 

Net Income was $1.7 million with a net margin of 12% for the quarter ended December 31, 2013, versus net income of $1.8 million with net margin of 10% for the quarter ended December 31, 2012. The improvement of net margin was predominately a result of improvements in our gross margins with reasonable sales and marketing expenditure. 

Balance Sheet and Cash Flow

As of December 31, 2013, we had working capital totaling $40.4 million, including cash and cash equivalents of $31.3 million. Net cash provided by operating activities was $1.4 million for the six months ended December 31, 2013 versus net cash generated from operating activities as $ (0.7) million for the six months ended December 31, 2012. We had $(0.4) million and $(12.6) million cash used in investing activities for the six months ended December 31, 2013 and 2012, respectively. We expect further increase in the net cash used in investing activities in association with our QLF relocation project throughout the remainder of fiscal year 2014. Net cash provided by financing activities for the six months ended December 31, 2013, totaled $3.2 million as compared to net cash provided by financing activities for the same period of 2012 of $3.5 million.

We believe that TPI is adequately funded to meet all of our working capital and capital expenditure needs for fiscal year 2014.

Business Development & Outlook

Research and Development (R&D)

The partnership-based R&D strategy supports TPI to commercialize, produce, and broaden our product pipeline and to market those products through our sales and marketing infrastructure. Currently, we have been monitoring the progress of several pipeline drugs with our partnership research institutes, of which we could be able to register intellectual property rights of these products upon milestone results.

R&D for additional indications of GMOL

Our flagship product GMOL (CFDA certification number: H20013079; patent number: 20061007800225) contributes significantly to our revenue. Clinical application and information gathered from physicians showed that in addition to our approved indication for GMOL: cardiovascular disorders, coronary heart disease and cerebral ischemic attack including strokes, off-label use of GMOL have been indicated in hepatic diseases and ophthalmological diseases. The validity of these observations is currently being investigated.

Jiangchuan Macrolide Project (JCM)

TPI has completed the 240-ton JCM facility for the R&D, manufacturing and sale of API and chemical intermediates of macrolide antibiotics. In January 2012, JCM was approved for its GMP certification designated as "CHUAN M0799," which is valid for the period of December 31, 2011 until December 31, 2015. Following the efficiency improvement and calibration, JCM started the production of the macrolide API for TPI's Azithromycin Dispersible Tablets (SFDA No: H20074145) since July 2012. Currently the monthly production capacity of JCM is 5 - 10 tons of Azithromycin macrolide API. The API produced by JCM is mainly to supply for TPI's own Azithromycin Tablets.

Tianyin Medicine Trading Distribution Business (TMT)

TMT is established to distribute products manufactured by both TPI and other pharmaceutical companies to fuel our expanding sales network as well as to provide synergy to our existing organic product portfolio. TMT has been distributing mainly TPI's own products since its inception in 2009. Since 2010, TPI has signed and later extended distribution contracts with Jiangsu Lianshui Pharmaceutical ("Lianshui") to distribute Lianshui-branded generic injection products including cough suppressant, antibiotics, anti-inflammatory medicines and other healthcare indications. On average, TMT distribution revenue contributed approximately $1-2 million sales per quarter.

Pre-extraction and formulation plant development at Qionglai Facility (QLF)

In preparation for the new Good Manufacturing Practice (GMP) standards stipulated by the PRC government in early 2011, TPI initiated a process to optimize the manufacturing facilities and production lines of the Company in compliance with the new GMP standards. We received our current GMP certificate for both of our pre-extraction plant and formulate facilities on August 27, 2013 for the next three years until the end of 2015. In addition, under the guidance by provincial government, our facility is scheduled to be relocated to Qionglai County, south of Chengdu, which is designated for the pharmaceutical industry. The Qionglai facility (QLF) post-relocation is approximately 18 miles from the Company's recently completed JCM facility. The proposed relocation project also includes our TCM pre-extraction plant which is currently located near the center of the city of Chengdu surrounded by a rapidly expanding residential area. Both the pre-extraction plant and the formulation plant will subsequently be relocated to Qionglai County to become a combined QLF plant, which is estimated to be 80 mu or approximately 13 acres. The combined QLF plant, designed and constructed according to the latest GMP standards, is expected to relieve the current capacity saturation at the current facilities. The re-location cost for Phase I (which includes relocation of both the formulation plant and pre-extraction plant) is estimated at $25 million, which, when completed, is expected to expand the current capacity by approximately 30%. If the Company decides to further expand the capacity, Phase II QLF, an additional $10 million may be invested to double the current capacity. Since the official start of the relocation project in February 2012, the construction of the QLF project has been progressing on schedule. The relocation of pre-extraction plant of Phase I has been initiated at the beginning of 2014 calendar year which will be immediately followed by the initiation of the relocation of formulation plant.

Fiscal 2014 Guidance

TPI continues to experience restrictive pricing pressures in the pharmaceutical market. The prevailing tightened pricing control of generic medicines in China from the government's efforts to promote lower margined essential drugs (EDL) compressed our margins as well as our sale volumes of those generics. These factors, together with the negative market environment of Azithromycin API pricing led to intensified market and pricing competition combined with an excess of capacity that may last for the next few years.

We reiterate the revenue forecast to range from 0% to 5% year over year growth from fiscal year 2013, with about 10% net margin. The net income guidance excludes any non-cash expenses associated with stock or stock options compensation plans. 

We believe the following factors will influence the future growth perspectives of TPI:

  1. Revenue growth of TPI's core product portfolio led by flagship product GMOL; 
  2. Gradual ramp up of JCM revenue in the fiscal year 2014;
  3. Stabilization of generic sales following the progressive pricing restrictions;
  4. Meaningful TMT distribution revenue contribution; and
  5. QLF relocation and smooth transition of production capacity.  

Management will continue to evaluate the Company's business outlook and communicate any changes on a quarterly basis or as when appropriate.

Conference Call

Senior management of TPI will host its earnings conference call for the second quarter of fiscal year 2014 ended December 31, 2013 to be held at 9:00 a.m. ET on Friday, February 14th, 2014.

Interested parties may access the call by dialing:

TOLL-FREE   

1-877-941-1428

TOLL/INTERNATIONAL  

1-480-629-9808

Conference ID:

4667572

It is advisable to dial in approximately 5 minutes prior to the start of the call.

Replay Dial-In Numbers:

TOLL-FREE  

1-877-870-5176

TOLL/INTERNATIONAL  

1-858-384-5517 

From: 

02/14/14 @ 12:00 pm Eastern Time

To: 

02/28/14 @ 11:59 pm Eastern Time

Replay Pin Number:  

4667572

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.viavid.com/index.php?id=107804

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list (EDL) of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit:  http://www.tianyinpharma.com

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact:

Investors Contact:

ir@tpi.asia  

Web:  

http://www.tianyinpharma.com  

Tel:

+86-28-8551-6696 (Chengdu, China)


+86 134-36-550011 (China)



Address:

23rd Floor Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China

 

Tianyin Pharmaceutical Co., Inc.

Consolidated Balance Sheets

(Unaudited)



December 31,



June 30,




2013



2013


Assets







Current assets:







Cash and cash equivalents


$

31,307,119



$

26,827,008


Restricted cash



-




4,536,000


Accounts receivable, net of allowance for doubtful accounts of $103,220 and $102,149 at December 31, 2013 and June 30, 2013, respectively



10,785,253




10,112,718


Inventory



6,037,270




6,036,014


Other current assets



-




313,320


Total current assets



48,129,642




47,825,060











Property and equipment, net



40,506,632




40,603,232


Intangibles, net



21,317,994




21,505,012


Goodwill



212,810




210,600


Total assets


$

110,167,078



$

110,143,904











Liabilities and Shareholders' Equity









Current liabilities:









Accounts payable and accrued expenses


$

1,466,397



$

1,352,560


Accounts payable – construction related



-




2,723,290


Short-term bank loans



4,583,600




5,929,200


Income tax and other taxes payable



1,196,355




1,442,111


Other current liabilities



472,403




449,062


Total current liabilities



7,718,755




11,896,223











Total liabilities



7,718,755




11,896,223











Equity









Stockholders' equity:









Preferred stock, $0.001 par value, 25,000,000 shares authorized, no shares issued and outstanding as of December 31, 2013 and June 30, 2013, respectively



-




-


Common stock, $0.001 par value, 50,000,000 shares authorized, 29,496,276 shares issued and 29,382,791 shares outstanding as of December 31, 2013 and June 30, 2013, respectively



29,496




29,496


Additional paid-in capital



30,134,852




30,134,852


Treasury stock



(135,925)




(135,925)


Statutory reserve



7,247,466




6,847,315


Retained earnings



53,825,888




50,967,308


Accumulated other comprehensive income



11,224,655




10,178,358


Total stockholders' equity - Tianyin Pharmaceutical Co., Inc.



102,326,432




98,021,404











Noncontrolling interest



121,891




226,277











Total equity



102,448,323




98,247,681











Total liabilities and equity


$

110,167,078



$

110,143,904


 

Tianyin Pharmaceutical Co., Inc.

Consolidated Statements of Operations

(Unaudited)
















For the Three Months Ended



For the Six Months Ended




December 31,



December 31,




2013



2012



2013



2012















Sales


$

13,923,166



$

17,603,298



$

28,671,714



$

33,574,995



















Cost of sales



7,705,869




10,799,516




16,460,902




20,527,509



















Gross profit



6,217,297




6,803,782




12,210,812




13,047,486



















Operating expenses

















Selling expenses



2,428,675




2,885,087




4,967,919




5,646,525


General and administrative expenses



1,082,395




1,097,854




2,111,161




2,219,387


Research and development



252,014




222,423




503,328




438,353


Total operating expenses



3,763,084




4,205,364




7,582,408




8,304,265



















Income from operations



2,454,213




2,598,418




4,628,404




4,743,221



















Other income (expenses):

















Interest income



86,424




31,842




108,734




99,444


Interest expense



(119,821)




(113,468)




(222,722)




(221,872)


Total other expenses



(33,397)




(81,626)




(113,988)




(122,428)



















Income before provision for income taxes



2,420,816




2,516,792




4,514,416




4,620,793



















Provision for income taxes



727,757




668,762




1,361,865




1,251,810



















Net income



1,693,059




1,848,030




3,152,551




3,368,983



















Less: net loss attributable to noncontrolling interest



(50,549)




(15,920)




(106,180)




(36,584)



















Net income attributable to Tianyin Pharmaceutical Co., Inc.


$

1,743,608



$

1,863,950



$

3,258,731



$

3,405,567



















Basic and diluted earnings per share


$

0.06



$

0.06



$

0.11



$

0.12



















Weighted average number of common shares outstanding:

















Basic and diluted



29,382,791




29,332,791




29,382,791




29,332,791


 

Tianyin Pharmaceutical Co., Inc.

Consolidated Statements of Comprehensive Income

(Unaudited)




















For the Three Months Ended



For the Six Months Ended




December 31,



December 31,




2013



2012



2013



2012



















Net income


$

1,693,059



$

1,848,030



$

3,152,551



$

3,368,983



















Other comprehensive income

















Foreign currency translation adjustment



435,429




226,799




1,048,091




114,299



















Total other comprehensive income



435,429




226,799




1,048,091




114,299



















Total Comprehensive income



2,128,488




2,074,829




4,200,642




3,483,282



















Less: Comprehensive income attributable to the noncontrolling interest



(49,912)




(15,225)




(104,386)




(36,249)



















Comprehensive income attributable to Tianyin Pharmaceutical Co., Inc.


$

2,178,400



$

2,090,054



$

4,305,028



$

3,519,531



 

Tianyin Pharmaceutical Co., Inc.

Consolidated Statements of Cash Flows

(Unaudited)










For the Six Months Ended




December 31,




2013



2012


Cash flows from operating activities:







Net Income


$

3,152,551



$

3,368,983


Adjustments to reconcile net income to net cash provided by (used in) operating activities:









Depreciation and amortization



1,297,519




1,171,649


Share-based payments



-




17,730


Changes in current assets and current liabilities:









Accounts receivable



(563,334)




786,045


Inventory



61,748




(1,099,581)


Other current assets



314,887




628,465


Accounts payable and accrued expenses



99,102




(319,349)


Accounts payable – construction related



(2,736,906)




(329,684)


Trade notes payable



-




(4,679,585)


Income tax payable and other taxes payable



(259,470)




(170,821)


Other current liabilities



18,527




(33,539)











Net cash provided by (used in) operating activities



1,384,624




(659,687)











Cash flows from investing activities:









Additions to property and equipment



-




(1,002,716)


Advance payments – construction and equipment



-




(5,298,242)


Additions of construction in progress



(367,234)




(6,123,118)


Acquisition of subsidiary – Hengshuo (HSP)



-




(206,219)











Net cash used in investing activities



(367,234)




(12,630,295)











Cash flows from financing activities:









Restricted cash



4,558,680




3,537,449


Proceeds from short-term bank loans



4,558,680




-


Repayment on short-term bank loans



(5,958,846)




-


Net cash provided by financing activities



3,158,514




3,537,449











Effect of foreign currency translation on cash



304,207




39,891











Net increase(decrease) in cash and cash equivalents



4,480,111




(9,712,642)











Cash and cash equivalents – beginning of period



26,827,008




35,152,295











Cash and cash equivalents – ending of period


$

31,307,119



$

25,439,653











Supplemental disclosures of cash activities









Cash paid for interest


$

222,645



$

221,872


Cash paid for income taxes


$

1,340,918



$

1,390,391


 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow